FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Most children with multisystem inflammatory syndrome in children recover quickly, according to study findings.

More than 97 million US residents are served by US public water systems with detectable levels of contaminants, and disparities related to race, ethnicity, and socioeconomic status are apparent.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Automated analysis of 2D camera recordings can improve performance for detecting isolated REM sleep behavior disorder.

Vaccination prior to COVID-19 infection does not significantly affect neurologic symptoms in patients with long COVID.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Cutaneous lupus erythematosus is associated with an increased risk for ASCVD, similar to the risk seen in association with SLE.

Coach presence on code teams is significantly increased following a quality CPR coach training intervention within a pediatric ICU.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.